Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 12, 2026
Talphera, Inc. (TLPH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $4.3 million.
Revenue
$0
Net income
$-4.31M
-23.6% vs year-ago quarter
Operating cash flow
$-3.92M
-33.1% vs year-ago quarter
Free cash flow
$-2.25M
+23.2% vs prior quarter
EPS
$-0.10
Dividend per share
None
Shares outstanding
51.91M
+152.9% vs year-ago quarter
Net cash
—
Operating margin
-1474700.0%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TLPH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Mateo, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1427925
- Former names
- ACELRX PHARMACEUTICALS INC (until Dec 14, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1,000 | $0 |
| Operating income | -$3.9M | -$3.9M | -$3.5M | -$3.4M | -$3.7M |
| Net income | -$4.3M | -$2.6M | -$3.8M | -$4.4M | -$3.5M |
| Operating cash flow | -$3.9M | -$3.4M | -$2.4M | -$2.5M | -$2.9M |
| Total assets | $26.8M | $30.2M | $29.7M | $30.7M | $16.5M |
| Total liabilities | $12.4M | $11.7M | $12.7M | $11.6M | $9.9M |
| Stockholders' equity | $14.4M | $18.5M | $17.0M | $19.2M | $6.6M |
| Cash and investments | $17.1M | $21.1M | $20.4M | $21.3M | $6.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 22, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 10-K | Annual report | Mar 23, 2026 | Dec 31, 2025 |
All 962 Talphera, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.